Ophthalmic Viscosurgical Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The ophthalmic viscosurgical devices market size is expected to grow from USD 460 million in 2025 to USD 489.62 million in 2026 and is forecast to reach USD 668.95 million by 2031 at 6.44% CAGR over 2026-2031. This report is Segmented by Type (Cohesive, Dispersive, and Viscoadaptive), Source (Biological (Bacteria-Derived HA), and More), Application (Cataract Surgery, and More), End User (Hospitals, Specialty Ophthalmic Clinics, and More), and Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Ophthalmic Viscosurgical Devices Market Trends and Insights

Demographic Expansion of the Cataract-Prone Elderly Cohort

Disability-adjusted life years lost to cataract rose from 6.68 million in 2019 to 7.1 million in 2021 and could exceed 7.5 million by 2025 if incidence trends hold. A 2024 meta-analysis logged 17 million people blind and 83.5 million experiencing moderate-to-severe visual impairment from cataract in 2020. Hospitals in high-income countries now face six-week median waitlists for extraction slots, directly inflating baseline use of viscoelastic syringes. Every additional year of life expectancy raises the surgical funnel, ensuring that the ophthalmic viscosurgical devices market keeps outpacing the broader ophthalmology consumables sector. Forward bookings released in early 2025 underscore unmet demand, implying stronger device pull-through even when per-procedure dosing remains constant.

Escalating Incidence of Diabetes-Linked Ocular Complications

Adults with diabetes develop cataract earlier and more aggressively than non-diabetic peers, pulling forward first-surgery age and lengthening lifetime exposure to viscoelastics. Routine early screening raises intervention rates that spill over into glaucoma and vitrectomy indications. Manufacturers now emphasize formulas that temper postoperative intraocular pressure spikes, positioning such attributes as clinical differentiators. Surgeons treating younger diabetic cohorts favor viscoadaptives that preserve endothelial integrity, reinforcing premium-tier demand. The ophthalmic viscosurgical devices market therefore benefits from a double-lift of larger patient cohorts and higher-value product mix.

Price Sensitivity and Reimbursement Caps on Premium OVD Grades

ASC payments are tethered to the hospital outpatient schedule, bundling viscoelastic costs into wider cataract reimbursement packages. When payment ceilings squeeze margins, procurement teams pivot toward mid-tier formulations or negotiate bulk discounts. European hospitals operating under value-based budgets demand peer-reviewed endothelial cell-loss data before approving costlier upgrades, favoring companies that fund robust clinical-support programs. This reimbursement compression moderates premium-mix expansion within the ophthalmic viscosurgical devices market without derailing overall volume growth.

Other drivers and restraints analyzed in the detailed report include:

• Technological Evolution in Phaco, Femto and MIGS Platforms
• Growing Surgical Capacity via ASCs and National Blindness-Prevention Programs
• Availability of Low-OVD or OVD-Free Surgical Techniques

Segment Analysis

Dispersive agents accounted for the largest 37.33% share of the ophthalmic viscosurgical devices market size in 2025, benefiting from their ability to coat delicate tissue during nucleus disassembly. Surgeons manage complex cataract presentations - pseudoexfoliation, shallow chambers, post-LASIK cases - by alternating dispersive and cohesive OVDs within a single procedure, lifting per-case volume. Innovators now embed anti-oxidant additives into dispersive formulations, defending price points even in cost-sensitive tenders.

Viscoadaptive blends are expanding fastest at a 7.59%CAGR to 2031, propelled by premium intraocular lens (IOL) cases that demand superior endothelial protection. These agents behave cohesively under low shear and disperse under high flow, maintaining chamber stability during phacoemulsification or femtosecond fragmentation. Manufacturers tie viscoadaptive syringes to injector systems, locking in surgeon loyalty and deepening penetration of the ophthalmic viscosurgical devices market.

Bacteria-derived hyaluronic acid secured a 39.02% slice of the ophthalmic viscosurgical devices market share in 2025, prized for consistent chain length and low immunogenicity. Hospitals align these products with sustainability scorecards that favor animal-free sourcing. Supply reliability further cements the segment’s leadership.

Semi-synthetic/fermentation grades are slated for an 8.74%CAGR through 2031. Fermentation allows rapid scale-up and precise molecular-weight control, enabling custom blends for combined cataract-glaucoma cases. Procurement teams appreciate insulation from livestock disease shocks, increasing the strategic appeal of fermentation routes within the ophthalmic viscosurgical devices market. Animal-derived sources retain a foothold on price but are ceding ground as regulators endorse animal-protein reduction.

Complete Report Scope:

• By Type
  • Cohesive
  • Dispersive
  • Viscoadaptive
• By Source
  • Biological (Bacteria-Derived HA)
  • Animal (Rooster Comb, Porcine, Bovine)
  • Semi-Synthetic / Fermentation-Based
• By Application
  • Cataract Surgery
  • Corneal Grafting / Keratoplasty
  • Other Applications
• By End User
  • Hospitals
  • Specialty Ophthalmic Clinics
  • Ambulatory Surgery Centers (ASCs)
  • Other End-users
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America represented 37.58% of the global ophthalmic viscosurgical devices market size in 2025, underpinned by robust reimbursement and dense ophthalmologist distribution. Medicare confirms cataract extraction as the top surgical episode in ASCs at roughly 19% of volume. Nearly 27.8% of U.S. adults aged 71+ report visual impairment, reinforcing surgical load. Bundled purchase agreements that link viscoelastic with phaco tips and IOL injectors are gaining traction, cementing supplier lock-in.

Asia-Pacific posts the highest 7.68%CAGR to 2031. Expanding health insurance in China and India drives cataract penetration, while provincial facilities transition to femtosecond platforms needing advanced viscoelastics. Surveys from Southwest China reveal a rising share of cataract patients with prior refractive surgery or high myopia. As reimbursement begins to acknowledge premium IOLs, dual-action viscoadaptives capture surgeon preference, lifting regional mix and directing incremental revenue into the ophthalmic viscosurgical devices market.

Europe sustains a sizable base yet faces tighter value-based procurement. Hospitals demand head-to-head endothelial cell-loss data before approving premium upgrades, favoring firms with strong clinical-evidence budgets. Regional societies advocate electronic instructions for use, aiming to cut intraocular lens packaging emissions by 67%. Early compliance with eco-qualified packaging may enhance tender scores and preserve share in the ophthalmic viscosurgical devices market.

List of Companies Covered in this Report:

• Alcon
• Johnson & Johnson
• Bausch + Lomb Inc.
• Carl Zeiss
• Beckton Dickinson
• Rayner Intraocular Lenses Ltd.
• Bohus Biotech
• Truviz Ophthalmic Pvt. Ltd.
• Amring Pharmaceutical
• Advin Health Care
• MicroSurgical Technology (MST)
• Lifecore Biomedical
• Contamac Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support